Researchers conducted a retrospective study at a hospital in Japan between April 2013 and March 2016. They compared three study periods:
• SP1: Patients receiving anti-methicillin-resistant Staphylococcus aureus agents and carbapenems for more than 14 days
• SP2: Patients receiving specific antimicrobials for more than 14 days
• SP3: Patients receiving specific antimicrobials regardless of the duration of treatment
Here are five study findings:
1. The timing of the antimicrobial stewardship team’s intervention reduced from an average of 15.5 days after administration in SP1 to 4.2 days in SP3.
2. The antimicrobial use density of carbapenems and piperacillin-tazobactam decreased significantly from SP2 to SP3.
3. The cost of specific antimicrobials decreased from $1.08 million in SP1 to $944,000 in SP2 and $763,000 in SP3.
4. The mortality rate and length of stay did not change during the study periods.
More articles on healthcare quality:
Virus season hits Pennsylvania early: 3 things to know
Therapy dogs may spread MRSA to pediatric patients, Johns Hopkins study finds
FDA: Adults under 45 now eligible for HPV vaccine
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
